肺腺癌（LUAD）是导致癌症相关死亡的主要原因，每年全球超过一百万人死于此病。免疫原性细胞死亡（ICD）能引发适应性免疫应答。然而，ICD相关的长链非编码RNA（lncRNA）在LUAD中的作用尚不清楚。在本研究中，我们研究了LUAD中肿瘤微环境的特征，ICD相关lncRNAs的预后意义以及潜在化疗药物的半最大抑制浓度（IC50）。我们使用单变量Cox回归对预后lncRNAs进行了排序，并基于它们构建了一个风险签名。然后，我们验证了模型的准确性，并生成了一个判分卡。此外，我们进行了免疫微环境分析、体细胞突变计算、肿瘤免疫功能和排斥（TIDE）分析以及抗癌药物IC50预测。最小绝对收缩和选择算子Cox回归鉴定了与ICD相关的27个预后lncRNAs，并构建了一个独特的风险签名，其中包含10个ICD相关的lncRNAs。风险分数被证实是一个可靠的预测生存的指标，具有最高的c-统计量得分。该签名具有卓越的预测性能与临床适用性，能够准确预测LUAD的总体生存。此外，lncRNA签名与免疫细胞浸润密切相关。我们还分析了风险分数、肿瘤浸润免疫细胞以及预后之间的相关性，并确定了低风险患者中高免疫和ESTIMATE评分。此外，我们观察到高风险患者中的检查点基因表达升高，TIDE评分较低，表明良好的免疫治疗反应。最后，我们发现高风险患者对抗癌药物易感。因此，我们独特的由10个ICD相关的lncRNAs构成的风险签名被证明可以指示LUAD中肿瘤和免疫微环境的特征，预测患者的总体生存，并指导个体化治疗。© 2023 Sun and Zhang.

Lung adenocarcinoma (LUAD) is the leading cause of cancer-related deaths, accounting for over a million deaths worldwide annually. Immunogenic cell death (ICD) elicits an adaptive immune response. However, the role of ICD-related long noncoding RNAs (lncRNAs) in LUAD is unknown. In this study, we investigated the characteristics of the tumor microenvironment in LUAD, the prognostic significance of ICD-related lncRNAs, and the half-maximal inhibitory concentration (IC50) of possible chemotherapeutic drugs. We sorted prognostic lncRNAs using univariate Cox regression and constructed a risk signature based on them. We then confirmed the model's accuracy and generated a nomogram. Additionally, we performed immune microenvironment analysis, somatic mutation calculation, Tumor Immune Dysfunction and Exclusion (TIDE) analysis, and anticancer pharmaceutical IC50 prediction. Least absolute shrinkage and selection operator Cox regression identified 27 prognostic lncRNAs related to ICD, and a unique risk signature using 10 ICD-related lncRNAs was constructed. The risk score was confirmed to be a reliable predictor of survival, with the highest c-index score. The signature had a remarkable predictive performance with clinical applicability and could accurately predict the overall survival in LUAD. Furthermore, the lncRNA signature was closely associated with immunocyte invasion. We also analyzed the correlation between the risk score, tumor-infiltrating immune cells, and prognosis and identified high immune and ESTIMATE scores in low-risk patients. Moreover, we observed elevated checkpoint gene expression and low TIDE scores in high-risk patients, indicating a good immunotherapy response. Finally, high-risk patients were shown to be susceptible to anticancer medications. Therefore, our unique risk signature comprising 10 ICD-related lncRNAs was demonstrated to indicate the characteristics of the tumor-immune microenvironment in LUAD, predict patients' overall survival, and guide individualized treatment.© 2023 Sun and Zhang.